Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Account Payables: 2019-2025

Historic Change in Account Payables for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$7.4 million.

  • BridgeBio Pharma's Change in Account Payables fell 106.39% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 53.33%. This contributed to the annual value of $1.5 million for FY2024, which is 45.61% down from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Change in Account Payables is -$7.4 million, which was down 604.45% from -$1.1 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Change in Account Payables high stood at $17.6 million for Q1 2025, and its period low was -$11.7 million during Q3 2021.
  • Moreover, its 3-year median value for Change in Account Payables was -$1.1 million (2025), whereas its average is $1.2 million.
  • Within the past 5 years, the most significant YoY rise in BridgeBio Pharma's Change in Account Payables was 5,061.41% (2024), while the steepest drop was 618.88% (2024).
  • BridgeBio Pharma's Change in Account Payables (Quarterly) stood at $1.5 million in 2021, then declined by 6.59% to $1.4 million in 2022, then surged by 349.42% to $6.2 million in 2023, then crashed by 160.56% to -$3.7 million in 2024, then slumped by 106.39% to -$7.4 million in 2025.
  • Its last three reported values are -$7.4 million in Q3 2025, -$1.1 million for Q2 2025, and $17.6 million during Q1 2025.